Clearside Biomedical

General Information

We are a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. Our current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space, or SCS, adjacent to the choroid, using our proprietary SCS Microinjector. With the SCS injection, our product candidates are more directly administered to the retina and choroid as compared to other ocular drug delivery techniques, such as intravitreal injections.

Employees: 21
Founded: 2011
Contact Information
Address 1220 Old Alpharetta Road, Suite 300, Alpharetta, GA 30005, US
Phone Number (678) 270-3631
Web Address
View Prospectus: Clearside Biomedical
Financial Information
Market Cap $137.2mil
Revenues $0.5 mil (last 12 months)
Net Income $-19.3 mil (last 12 months)
IPO Profile
Symbol CLSD
Exchange NASDAQ
Shares (millions): 7.2
Price range $7.00 - $7.00
Est. $ Volume $50.4 mil
Manager / Joint Managers Cowen and Company/ Stifel
CO-Managers Needham & Company, Wedbush PacGrow
Expected To Trade: 6/2/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change